Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNNI3K | Q59H18 | 4/20 | 0.49 |
| ▸ | GSK3B | P49841 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 7/20 | 0.47 |
| ▸ | BCR | P11274 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4665691 | 0.92 | ABL1 (0.53) | TNNI3KGSK3BMAPTTP53GAA | |
| SCHEMBL4666197 | 0.85 | ABL1 (0.53) | MAPTTP53GAATHRBSMN1; SMN2 | |
| SCHEMBL4665747 | 0.84 | MAPT (0.62) | GSK3BMAPTTP53SMN1; SMN2ABL1 | |
| SCHEMBL4666116 | 0.83 | ABL1 (0.53) | TP53ABL1BCRMEN1KMT2A | |
| SCHEMBL4665732 | 0.82 | MAPT (0.67) | TNNI3KMAPTTP53GAATHRB | |
| SCHEMBL4666113 | 0.81 | ABL1 (0.49) | TP53ABL1BCRMEN1KMT2A | |
| SCHEMBL4665727 | 0.78 | GSK3B (0.47) | TNNI3KGSK3BABL1BCRMEN1 | |
| SCHEMBL4663910 | 0.77 | AXL (0.51) | TNNI3KGSK3BABL1BCRMEN1 | |
| SCHEMBL4665875 | 0.77 | HTR6 (0.51) | TNNI3KGSK3B | |
| Formic Acid SCHEMBL4667535 | 0.76 | GSK3B (0.44) | TNNI3KGSK3BABL1BCRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242681-A1 | N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors | ALTANA PHARMA AG (DE) | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242681-A1 | N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors | MAP3K19, MAP3K6, MAP3K20 | TNNI3K 25/4885GSK3B 1516/4885MAPT 4521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.